Rheumatoid Arthritis
Conditions
Keywords
Methotrexate insufficient responders
Brief summary
* Ninety patients suffering from active rheumatoid arthritis despite continued treatment with methotrexate will be evaluated for improvement of disease activity when taking GLPG0634 (4 different doses will be evaluated) or matching placebo for 4 weeks. * During the course of the study, patients will also be examined for any side effects that may occur, and the amount of GLPG0634 present in the blood as well as the effects of GLPG0634 on disease- and mechanism of action-related parameters in the blood will be determined.
Interventions
DRUGGLPG0634
DRUGPlacebo
Sponsors
Galapagos NV
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Have active RA as shown by five or more swollen joints (from the 66-joint count), five or more tender joints (from 68-joint count), and a serum CRP ≥1.0 mg/dL; * Have received methotrexate for 12 weeks or longer and at a stable dose of 7.5 to 25 mg/week for at least 4 weeks prior to screening and willing to continue on this regimen for the duration of the study; * If taking oral steroids, these should be at a dose ≤10 mg/day of prednisone or prednisone equivalent and stable for at least 4 weeks prior to screening; * If taking non-steroidal anti-inflammatory drugs (NSAIDs), these must be at a stable dose for at least 2 weeks prior to screening; * Female subjects must have a negative pregnancy test unless they are surgically sterile or have been post-menopausal for at least one year; * Women of childbearing potential must use a medically acceptable means of birth control and agree to continue its use during the study and for at least 12 weeks after the last dose of study drug. * Sexually active men must agree to use a medically acceptable form of contraception during the study and continue its use for at least 3 months after the last dose of study drug; and * Able and willing to sign the informed consent prior to screening evaluations and agree to schedule of assessments.
Exclusion criteria
* Treatment with disease-modifying antirheumatic drugs (DMARDs), other than background methotrexate; * Current or previous RA treatment with a biological agent, with the exception of biologics administered in a clinical study setting more than six months prior to screening (12 months for rituximab or other B cell depleting agents); * Previous treatment at any time with a cytotoxic agent, other than methotrexate, before screening; * Previous use of the study drug GLPG0634; * Receipt of an intra-articular or parenteral corticosteroid injection within 4 weeks prior to screening; * Known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug as determined by the Investigator; * Positive serology for HIV1 or 2 or hepatitis B or C, or any history of hepatitis from any cause with the exception of hepatitis A; * History of any inflammatory rheumatological disorders other than RA; * History of tuberculosis (TB) infection
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The number of patients with an ACR20 score at Week 4 as a measure of efficacy | Week 4 (end of treatment visit) | To preliminary evaluate the efficacy of GLPG0634 compared to placebo in terms of the proportion of subjects achieving an ACR20 response at Week 4 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The number of patients with ACR20/50/70 response, time to response and DAS28 score at every visit as a measure of efficacy | From Day -1 up to end of treatment visit (week 4) | To evaluate the efficacy of GLPG0634 compared to placebo in terms of ACR response criteria at every visit (ACR20, ACR50, ACR70), time to response, and disease status (DAS28\[C-reactive protein, CRP\] |
| The number of patients with adverse events, abnormal lab tests, vital signs and ECG as a measure of safety and tolerability | From screening up to 10 days after last dose | To evaluate the safety and tolerability of GLPG0634 in comparison with placebo in terms of adverse events (AEs), laboratory test abnormalities, vital signs and electrocardiogram (ECG) |
| The plasma levels of GLPG0634 as a measure of PK | Week 1, week 2 and week 4 visits | To characterize the pharmacokinetics (PK) of GLPG0634 by measuring the amount of GLPG0634 in the plasma |
| The plasma levels of GLPG0634 and MTX as a measure of PK | Day -1 and Week 2 or 4 visit (8 hour-sampling) | To explore the potential interaction of GLPG0634 on MTX by assessing steady state PK in an 8-hour sampling at Day -1 and at Week 2 or Week 4 visit in a subset of patients |
| The levels of immune- and inflammation-related parameters in plasma as a measure of PD | Day -1, Week 1, week 2 and week 4 visits | To characterize the pharmacodynamics (PD) of GLPG0634 by measuring the levels of immune- and inflammation-related parameters in plasma |
Countries
Hungary, Moldova, Russia, Ukraine
Outcome results
None listed